Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MIV Therapeutics has entered into an agreement to sell all of its issued and outstanding shares of SagaX to Israeli-based Shimoco in consideration of the repayment of $4 million plus future royalties on sales of 8%.
Subscribe to our email newsletter
The payments will be made in increments of $1 million upon the achievement of various equity financing parameters which may be met by SagaX over a four-year period from closing.
Shimoco is owned and controlled by Dov Shimon, the founder of SagaX, who has resigned from his position on the company’s board of directors as a consequence of the entering into of the share purchase agreement. The closing of the share purchase agreement is subject to numerous conditions.
Mark Landy, president of MIV Therapeutics, said: “This transaction is a win-win for all parties. The sale of SagaX will allow MIV to better focus on its goal of being a leader in the interventional cardiology space, and saves us in excess of $1 million or more annually in development costs, while freeing up SagaX to pursue other financing avenues. SagaX is developing an aortic embolic protection device, a potentially important medical device for which there is great need. This transaction also allows us to participate in potential future product sales via royalty payments.”